After the first dose of vaccination, patients with HM had significantly lower seroconversion rates than controls (33.3% and 74.9%, respectively), especially in chronic lymphocytic leukemia (CLL) patients and patients treated with anti-CD20 antibodies or BTKi. The gene discussed is IBTK; the disease is B-cell chronic lymphocytic leukemia.